<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2300">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04495764</url>
  </required_header>
  <id_info>
    <org_study_id>20-M-0044-00</org_study_id>
    <nct_id>NCT04495764</nct_id>
  </id_info>
  <brief_title>Registry of Sustained Immunity to COVID-19 Among ESKD Patients</brief_title>
  <acronym>RePAiR</acronym>
  <official_title>Registry of Sustained Immunity to COVID-19 Among ESKD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Davita Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Davita Clinical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective registry study of subjects undergoing hemodialysis for&#xD;
      treatment of end-stage renal disease in a DaVita center.&#xD;
&#xD;
      The objective of this study is to understand whether and to what degree anti-SARS-CoV-2&#xD;
      antibodies mitigate the risk of subsequent SARS-CoV-2 infection and COVID disease within the&#xD;
      ESKD population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, prospective registry study of subjects undergoing hemodialysis for&#xD;
      treatment of end-stage renal disease in a DaVita center.&#xD;
&#xD;
      The objective of this study is to understand whether and to what degree anti-SARS-CoV-2&#xD;
      antibodies mitigate the risk of subsequent SARS-CoV-2 infection and COVID disease within the&#xD;
      ESKD population.&#xD;
&#xD;
      Following informed consent, participants will undergo baseline serologic characterization for&#xD;
      anti-SARS-CoV-2 IgM and IgG. The study is planned to align with the present wave of COVID-19.&#xD;
      Enrollment will continue until the total sample size of 2500 is reached or until the study&#xD;
      sponsor determines. Should there be a subsequent wave of COVID- 19, participants will be&#xD;
      actively surveiled for evidence of SARS-CoV-2 infection and for COVID-19 disease. The&#xD;
      relationship between baseline serologic status and subsequent infection/disease will be&#xD;
      determined.&#xD;
&#xD;
      This study will have 2 distinct phases.&#xD;
&#xD;
      Phase 1 (baseline characterization) start will be triggered by the sponsor and may start at&#xD;
      different times at the active sites. Participants will be consented and enrolled and blood&#xD;
      will be collected for anti-SARS-CoV-2 antibodies.&#xD;
&#xD;
      Phase 2: Start will be triggered by the sponsor in the fall of 2020 and each geographic study&#xD;
      location may be triggered to start at separate times. Study participants will be followed&#xD;
      prospectively for incidence and severity of COVID-19. Study visits will commence upon sponsor&#xD;
      trigger and will occur once monthly for 4 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 20, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-SARS-CoV-2 antibodies</measure>
    <time_frame>Through study completion (5 visits), an average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of COVID-19</measure>
    <time_frame>Through study completion (5 visits), an average of 6 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">2504</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <condition>Anti-SARS-CoV-2 Infection</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Baseline serologic characterization for anti-SARS-CoV-2 IgM and IgG&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Between ≥18 and 80 years of age, inclusive.&#xD;
&#xD;
          2. Ability to provide informed consent.&#xD;
&#xD;
          3. Currently receiving hemodialysis treatment for end-stage kidney disease at a DaVita&#xD;
             dialysis center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between ≥18 and 80 years of age, inclusive.&#xD;
&#xD;
          -  Ability to provide informed consent.&#xD;
&#xD;
          -  Currently receiving hemodialysis treatment for end-stage kidney disease at a DaVita&#xD;
             dialysis center.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesca Tentori, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Davita Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DCR Victorville</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>92394</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCR Connecticut</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCR Twin Cities</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCR Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCR Bronx</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCR Canton</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCR El Paso</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79925</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCR Lewisville</name>
      <address>
        <city>Lewisville</city>
        <state>Texas</state>
        <zip>75057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCR San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCR San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCR Norfolk</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCR Milwaukee</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2020</study_first_posted>
  <last_update_submitted>December 31, 2020</last_update_submitted>
  <last_update_submitted_qc>December 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunoglobulin G</keyword>
  <keyword>Immunoglobulin M</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

